Summary In the BUPA study, a prospective study of 22,000 men attending a screening centre in London, the mean serum cholesterol level of the 267 men who developed cancer was 6.66mmoll-1, not significantly different from the mean level of 6.72mmoll-1 among the 525 unaffected controls matched for age, smoking history and the calendar quarter of their attendance at the screening centre. There was, however, a significant difference in serum cholesterol levels among men who were diagnosed as having cancer less than 2 years after the date of blood collection (6.49 mmol P-for the 116 cancer subjects and 6.78 mmol l-for the 224 controls (P= 0.02)) but not in men who developed cancer 2-11 years after blood collection (6.79 mmol P-for the 151 cancer subjects and 6.68 mmol l-for the 301 controls). The observation that the association between low serum cholesterol and cancer was confined to men in whom a diagnosis of cancer was made within 2 years after the date of blood collection suggests that the low serum cholesterol is a metabolic consequence rather than a precursor of the cancer. Our 
Studies in Western populations have shown that a low serum cholesterol is associated with an increased risk of cancer but it is not yet resolved whether this is entirely because cholesterol is lowered as a metabolic consequence of undiagnosed cancer, or if, as some studies suggest, there is also a long-term association between low cholesterol and cancer. We therefore decided to investigate this using data from the BUPA study, a prospective study of men attending a medical screening centre in London.
Subjects and methods
The design of our prospective study has been described before (Wald et al., 1980 (Wald et al., , 1986 . In summary, the population that was studied consisted of about 22,000 men aged 35-64 years who attended the British United Provident Association (BUPA) medical centre in London for a comprehensive medical examination (including a serum cholesterol measurement) between 1975 and 1982. The National Health Service records of these men were flagged and the Office of Population Censuses and Surveys informed us (up to the end of April 1986 for this analysis) of cancer notifications by site (through the National Cancer Registry) and of all deaths by cause. We here report on the same series of cancer subjects and controls as was previously used to examine the association of cancer with serum retinol, vitamin E and betacarotene (Wald et al., 1986 (Wald et al., , 1987 (Wald et al., , 1988 within a week of the men being seen. The change in method resulted in a shift of the serum cholesterol distribution: the mean fell by 0.43 mmol l-1, but there was no material change in the standard deviation. To allow for this, 0.43 mmol l-1 was added to serum cholesterol values obtained after the change. Relative risks were estimated using the conditional logistic regression method of Breslow & Day (1980) which allows for the matched design. Table I shows the mean cholesterol concentration of subjects and matched controls, both for all cancer and for the same specific sites as used in our previous analyses (Wald et al., 1987) , classified according to the interval between blood collection and the diagnosis of cancer. The mean serum cholesterol level for all the cancer subjects was similar to that for their controls (6.66 and 6.72 mmol 1-I respectively (P>0.2)). Subjects whose cancer was diagnosed two or more years after blood collection also had a similar mean cholesterol level to their controls (6.79 and 6.68 mmol -1 respectively (P>0.2)). However, the mean cholesterol level was lower in subjects whose cancer was diagnosed before two years atter the date of blood collection (6.49 in subjects and 6.78 mmol I -I in controls (P = 0.02)).
Results
Interpretation of the results for individual cancer sites is limited by the smaller numbers of subjects available. However, the same pattern of an association with low cholesterol in the short-term, but not in the long-term, was apparent in the mean values for a number of the individual cancer sites (Table I) , and there was no evidence that the sites differed in this regard (statistical test for heterogeneity, P>0.2). Table II shows the mean serum cholesterol level in all cancer subjects and matched controls according to the interval between blood collection and the diagnosis of cancer. Among subjects who had blood taken within a year of diagnosis, the mean serum cholesterol was 0.32 mmol -1 (4.7%) lower than among controls (P=0.02). As the interval increased, the difference diminished and, after three or more years, the mean serum cholesterol in subjects was in fact slightly higher (though not significantly so) in subjects than in controls. This trend was statistically significant (P=0.02). Table III shows the relative risk of any cancer according to the quintile of serum cholesterol level and according to the interval between blood collection and the diagnosis of aRelative risks take into account the matched design of the study and are expressed relative to the risk in the 'all' category; bBecause the original cholesterol levels were taken to the nearest 0.1 mmol 1-1, the'quintiles' do not contain equal numbers; CTest for trend, P=0.01; dTest for trend, P>0.2.
cancer (<2 years and 2 years). For those diagnosed earlier there was a statistically significant declining trend in relative risk from the lowest to the highest cholesterol quintile, but this was not the case for those diagnosed later. In these data, there was no evidence of an association between serum cholesterol and the age of the subjects and controls. The mean cholesterol was, on average, 0.1 Immol 1 -(s.e. = 0.08) higher in current smokers than in non-smokers, but in current smokers of cigarettes alone, there was no evidence of an association between cholesterol and cigarette consumption. Thus the matching for age and smoking habit were less important in this study on serum cholesterol than in our previous studies of serum betacarotene and vitamin E based on the same series of cancer subjects and controls (Wald et al., 1987 (Wald et al., , 1988 .
Discussion
In our study the inverse association between serum cholesterol and cancer that others have found was restricted to cancers diagnosed less than 2 years after the date of blood collection. Our data therefore suggest that the low serum cholesterol was a metabolic consequence, rather than a precursor, of the cancer. It follows that a lowered serum cholesterol should not be regarded as a cause of cancer. We have not been able to consider many sites of cancer separately since our study was not large enough to do so.
Most studies, as well as our own, show that the low cholesterol-cancer association is either entirely confined to the short-term (a few years) (Hiatt & Fireman, 1986; Wingard et al., 1984; Salonen, 1982; Wallace et al., 1982; Thomas et al., 1982; Kromhout et al., 1988) or is substantially so; any longer-term association being less marked than the short-term association and no longer statistically significant (Sherwin et al., 1987; International Collaborative Group, 1982; Keys et al., 1985; Gerhardsson et al., 1986; Sorlie & Feinleib, 1982) . Some studies, however, show a persistent longer-term association that is of comparable magnitude to the short-term association which is most apparent with lung cancer and, in general, is statistically significant (Kagan et al., 1981; Garcia-Palmieri et al., 1981; Kark et al., 1980; Schatzkin et al., 1987; Morris et al., 1983) . The reason for the discrepancy is uncertain, but it is unlikely to be due to chance, The fact that a number of large and well conducted studies show no long-term association between low serum cholesterol and cancer at all sites or cancer at individual sites (including lung) makes it unlikely that the association found in some studies is causal and suggests that it is due to the effect of unidentified confounding factors or other sources of bias present in the studies concerned or the populations examined.
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